Trial Profile
A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 May 2014
Price :
$35
*
At a glance
- Drugs Cholyl lysyl fluorescein (Primary)
- Indications Liver cirrhosis; Non-alcoholic steatohepatitis
- Focus Diagnostic use
- Sponsors Norgine
- 21 May 2014 New trial record